Freenome
NASDAQ: FRNMLondon · Founded 2015 · United Kingdom corporation · 410 employees on LinkedIn · 15 known investors
Find your way into Freenome
491 people in our graph share verified history with the Freenome team — schools, employers, funds. One of them is your warm intro.
Luna Schmidunlockedknows Riley Ennis · together at Morgan Stanley (overlapped)
×5knows the team · via Morgan Stanley
×2knows the team · via Dartmouth College
×3knows the team · via The Johns Hopkins University
knows the team · via Foundation Medicine
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
Founders & leadership
Freenome was founded in 2015 by Riley Ennis, Charles Roberts, and Gabriel Otte.
RE
Riley EnnisinCo-Founder and Chief Product OfficerRiley Ennis co-founded Freenome, which develops blood-based cancer detection technology. Previously, he founded Immudicon/Oncolinx, a biotech company focused on immuno-oncology biologics targeting dendritic cell delivery and tumor microenvironment mechanisms, which partnered with multiple pharmaceutical companies.
CR
Charles RobertsinCo-founder
GO
Gabriel OtteinCEO, Co-founder2016–2021
Board
SL
Stuart LawsonBoard director
Investors · 15
RA Capital✓ verifiedBoston
AME Cloud VenturesPalo Alto · $1M – $10M
Andreessen HorowitzMenlo Park · $500K – $50M
Artis VenturesSan Francisco · $50K – $25M
Asset Management CompanyMenlo Park · $500K – $2M
Averin CapitalNew York
Bain Capital Life SciencesBoston
Catalio Capital Management, LPNew York
CRV (Charles River Ventures)Bay Area · $250K – $5M
DCVC (Data Collective)Palo Alto · $5M – $25M
EcoR1 CapitalSan Francisco
GV (Google Ventures)Mountain View · $250K – $50M
Kaiser Permanente VenturesSan Francisco · $2M – $5M
Roche Venture FundBasel · $648K – $3.2M
Agent CapitalreportedWaltham
Reported raises · per SEC filings
Form D private placements$800K disclosed across 1 round · 2015
▶$800KraisedOct 2015 · 4 investors · Other TechnologyRule 506(b)
▶$800KraisedOct 2015 · 4 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Stuart LawsonDirector
- Charles RobertsDirector
- Gabriel OtteDirector
- Offering amount
- $800K
- Amount sold
- $800K
- First sale
- Oct 2015
- Incorporated
- Corporation, United Kingdom, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
The Freenome mafia →8 people who came through Freenome went on to found or lead other companies.
Amir NashatBoard MemberFounded Paratus Sciences +2Daniel DelubacVP, Laboratory Technologies and OperationsFounded iOrganBioJonathan HirschAdvisor, Real World Evidence & Data PlatformFounded SynapticureJay ChiaML Infrastructure EngineerFounded EventualAbhinav GopalSoftware EngineerFounded RubbrbandDavid WeinbergDirector, Molecular ResearchFounded ParcelBioDima VremenkoSoftware Engineer InternFounded InkboxJay ChiaMachine Learning Platform EngineerFounded Eventual
Competitors · 10
by search overlap
Immunome29 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Myome21 shared keywordsMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
Alterome Therapeutics, Inc.21 shared keywordsAlterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Cellanome20 shared keywordsCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
Noveome Biotherapeutics20 shared keywordsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
Bioworld17 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Metronome17 shared keywordsMetronome provides a usage-based billing platform for SaaS companies, enabling them to launch products faster and make data-driven revenue decisions. The platform handles billing operations at scale, allowing companies to iterate pricing strategies and connect billing to product experiences.
healthOme16 shared keywordsHealthŌme combines insurance with health navigation services to improve how patients access, finance, and receive precision healthcare.
Nucleome15 shared keywordsNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
Zip Drug12 shared keywordsZipdrug is a prescription delivery and pharmacy benefit platform, acquired by Anthem's PBM IngenioRx in 2020.
Companies competing with Freenome for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Freenome do?
- Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
- Who founded Freenome?
- Freenome was founded by Riley Ennis, Charles Roberts, Gabriel Otte in 2015.
- Who are Freenome's investors?
- Freenome's investors include RA Capital, AME Cloud Ventures, Andreessen Horowitz, Artis Ventures, Asset Management Company, Averin Capital, Bain Capital Life Sciences, Catalio Capital Management, LP and 7 more.
- How much funding has Freenome raised?
- Freenome has disclosed $800K raised across 1 round.
- Where is Freenome headquartered?
- Freenome is headquartered in London.